NO20090053L - Metoder for behandling av cancer ved anvendelse av TAK1 inhibitorer - Google Patents

Metoder for behandling av cancer ved anvendelse av TAK1 inhibitorer

Info

Publication number
NO20090053L
NO20090053L NO20090053A NO20090053A NO20090053L NO 20090053 L NO20090053 L NO 20090053L NO 20090053 A NO20090053 A NO 20090053A NO 20090053 A NO20090053 A NO 20090053A NO 20090053 L NO20090053 L NO 20090053L
Authority
NO
Norway
Prior art keywords
cancer
treatment
methods
tak1 inhibitors
tak1
Prior art date
Application number
NO20090053A
Other languages
English (en)
Norwegian (no)
Inventor
Kate Byth
Sangeetha Palakurthi
Lihua Yu
Qi Zhang
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20090053L publication Critical patent/NO20090053L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20090053A 2006-07-10 2009-01-06 Metoder for behandling av cancer ved anvendelse av TAK1 inhibitorer NO20090053L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80684506P 2006-07-10 2006-07-10
PCT/GB2007/002568 WO2008007072A2 (fr) 2006-07-10 2007-07-10 Procédé d'inhibition cellulaire

Publications (1)

Publication Number Publication Date
NO20090053L true NO20090053L (no) 2009-02-06

Family

ID=38920633

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090053A NO20090053L (no) 2006-07-10 2009-01-06 Metoder for behandling av cancer ved anvendelse av TAK1 inhibitorer

Country Status (12)

Country Link
US (1) US20090312396A1 (fr)
EP (1) EP2041303A2 (fr)
JP (1) JP2009544583A (fr)
KR (1) KR20090027735A (fr)
CN (1) CN101490279A (fr)
AU (1) AU2007274055A1 (fr)
BR (1) BRPI0714158A2 (fr)
CA (1) CA2658163A1 (fr)
IL (1) IL196208A0 (fr)
MX (1) MX2009000376A (fr)
NO (1) NO20090053L (fr)
WO (1) WO2008007072A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9101559B2 (en) * 2009-05-08 2015-08-11 New York University Leukemic cell CNS infiltration controlled by notch-induced chemotaxis
GB0918579D0 (en) 2009-10-22 2009-12-09 Imp Innovations Ltd Gadd45beta targeting agents
CN101968491A (zh) * 2010-09-29 2011-02-09 上海生物芯片有限公司 弥漫性大b细胞淋巴瘤分子病理分型方法及试剂盒和应用
GB201107118D0 (en) 2011-04-27 2011-06-08 Imp Innovations Ltd Method of diagnosis and prognosis
US20140243403A1 (en) * 2011-06-03 2014-08-28 The General Hospital Corporation Treating colorectal, pancreatic, and lung cancer
WO2013012998A1 (fr) 2011-07-19 2013-01-24 Emory University Inhibiteurs de kinase tak1, compositions et utilisations associées
CA2932351A1 (fr) 2013-12-13 2015-06-18 Dana-Farber Cancer Institute, Inc. Procede pour traiter un lymphome lymphoplasmocytaire
US9908872B2 (en) 2013-12-13 2018-03-06 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
EP3209648B1 (fr) 2014-10-22 2020-03-11 Dana-Farber Cancer Institute, Inc. Composés contenant des groupes thiazolyle pour le traitement de maladies prolifératives
CN104911183B (zh) * 2015-06-25 2018-01-09 中山大学孙逸仙纪念医院 抑制胰腺癌TAK1基因表达的shRNA的转录模板
WO2018060452A1 (fr) * 2016-09-30 2018-04-05 Fundació Institut Mar D'investigacions Mèdiques (Imim) Approches thérapeutiques contre le cancer
CN109420170B (zh) * 2017-08-25 2021-03-02 中国科学院上海营养与健康研究所 肿瘤微环境相关靶点tak1及其在抑制肿瘤中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004025362A1 (de) * 2004-05-19 2005-12-22 Sanofi-Aventis Deutschland Gmbh Verwendung der TGFbeta-aktivierten Kinase 1
WO2006023210A2 (fr) * 2004-07-23 2006-03-02 Aveo Pharmaceuticals, Inc. Gene gp132: techniques et compositions de traitement du cancer
WO2007044571A2 (fr) * 2005-10-06 2007-04-19 President And Fellows Of Harvard College Procedes permettant d'identifier des proteines essentielles a la proliferation des cellules humaines, et agents therapeutiques diriges contre ces proteines

Also Published As

Publication number Publication date
WO2008007072A3 (fr) 2008-05-08
CN101490279A (zh) 2009-07-22
MX2009000376A (es) 2009-03-09
BRPI0714158A2 (pt) 2012-12-25
AU2007274055A1 (en) 2008-01-17
WO2008007072A2 (fr) 2008-01-17
IL196208A0 (en) 2009-09-22
CA2658163A1 (fr) 2008-01-17
US20090312396A1 (en) 2009-12-17
KR20090027735A (ko) 2009-03-17
WO2008007072A8 (fr) 2009-02-26
JP2009544583A (ja) 2009-12-17
EP2041303A2 (fr) 2009-04-01

Similar Documents

Publication Publication Date Title
NO20090053L (no) Metoder for behandling av cancer ved anvendelse av TAK1 inhibitorer
PH12020500203A1 (en) Identification of lkb1 mutation as a predictive boimarker for sensitivity to tor kinase inhibitors
EA201490814A1 (ru) Лечение злокачественной опухоли ингибиторами tor-киназы
DE602007012677D1 (de) Verfahren zur behandlung von zellproliferationsstörungen mit pyrimidindiaminverbindungen
EP2331530B8 (fr) Composés multicycliques fusionnés en tant qu inhibiteurs des protéines kinases
EA201270752A1 (ru) Ингибиторы киназы и способ лечения злокачественной опухоли с их помощью
MX2013004086A (es) Metodos para inhibir proliferacion celular en cancers accionados por egfr.
WO2012016133A3 (fr) Inhibiteurs de la ros1 kinase pour le traitement de glioblastome et d'autres cancers déficients en p53
MX2012000709A (es) Inhibidores de pirrolopiridina de cinasas.
IN2012DN03012A (fr)
MX2009006542A (es) Inhibidores de histona desacetilasa y sus profarmacos.
WO2009134658A3 (fr) Composés de pyrimidine bicycliques fusionnés en tant qu'inhibiteurs d'aurora kinase
MY147832A (en) Compounds for enzyme inhibition
NO20082683L (no) Neuroendokrin tumorbehandling
WO2006055635A3 (fr) Compositions et methodes de modification de la signalisation autocrine wnt
WO2008031820A3 (fr) Combinaisons d'inhibiteurs de l'histone désacétylase spécifiques de la classe i et d'inhibiteurs du proétasome
WO2010042933A3 (fr) Inhibition et traitement des métastases du cancer de la prostate
UA115455C2 (uk) Спосіб одержання сполук для застосування при лікуванні раку
TN2012000205A1 (en) Method and compositions for treating solid tumors and other malignancies
PH12015500867A1 (en) Treatment of prostate cancer with tor kinase inhibitors
EA201101041A1 (ru) Производные пиридазинона
EA201001576A1 (ru) Тиенопиримидины
WO2008121467A3 (fr) Polythérapie pour le traitement du cancer
ATE540674T1 (de) Verwendung einer antikrebsverbindung
MX2009008073A (es) Inhibidores de epoxido hidrolasa solubles para el tratamiento de sindrome metabolico y trastornos relacionados.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application